KR960004322A - 알파-(4-클로로페닐)-4-((4-플루오로페닐)메틸)피페리딘-1-에탄올에스테르,그것의제법및치료학적적용 - Google Patents

알파-(4-클로로페닐)-4-((4-플루오로페닐)메틸)피페리딘-1-에탄올에스테르,그것의제법및치료학적적용 Download PDF

Info

Publication number
KR960004322A
KR960004322A KR1019950020426A KR19950020426A KR960004322A KR 960004322 A KR960004322 A KR 960004322A KR 1019950020426 A KR1019950020426 A KR 1019950020426A KR 19950020426 A KR19950020426 A KR 19950020426A KR 960004322 A KR960004322 A KR 960004322A
Authority
KR
South Korea
Prior art keywords
group
fluorophenyl
chlorophenyl
piperidine
methyl
Prior art date
Application number
KR1019950020426A
Other languages
English (en)
Inventor
쟝뽈떼노
죠나단프로스트
파뜨릭라르드놔
마리아까르멘르노느
알렉산더비크
Original Assignee
에. 뚜레 레베뜨르
신떼라보 소시에떼 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에. 뚜레 레베뜨르, 신떼라보 소시에떼 아노님 filed Critical 에. 뚜레 레베뜨르
Publication of KR960004322A publication Critical patent/KR960004322A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

일반식(Ⅰ)의 화합물 :
상기식에서 R은 직쇄 또는 선택적으로 분지쇄이고, 및/또는 선택적으로 에틸렌 결합을 함유하는 (C1-C19) 알킬기, (C3-C6) 시클로알킬기, (C3-C6) 시킬로알킬메틸기, 선택적으로 할로겐 원자로 치환된 페닐기, 또는 선택적으로 할로겐원자로 치환된 페닐메틸기를 나타낸다.
치료의 적응

Description

α-(4-클로로페닐)-4-[(4-플루오로페닐)메틸] 피페리딘-1-에탄올 에스테르,그것의 제법 및 치료학적 적용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 광학적으로 순수한 거울상 입체이성질체 또는 거울상 입체이성질체의 혼합물형태로 다음 일반식(Ⅰ)에 해당하는 유리염기 또는 부가염 형태의 화합물.
    상기식에서 R은 직쇄 또는 선택적으로 분지쇄이고, 및/또는 선택적으로 에틸렌 결합을 함유하는 (C1-C19) 알킬기, (C3-C6) 시클로알킬기, (C3-C6) 시킬로알킬메틸기, 선택적으로 할로겐 원자로 치환된 페닐기, 또는 선택적으로 할로겐원자로 치환된 페닐메틸기를 나타낸다.
  2. α-(4-클로로페닐)-4-[(4-플루오로페닐)메틸] 피페리딘-1-에탄올을 R이 제1항에 정의된 것과 같은 일반식 (RCO)2O의 무수물 또는 일반식 RCOCℓ의 산 염화물과 반응시키는 것을 특징으로 하는 제1항에 따른 화합물의 제조방법.
  3. 제1항에 따른 화합물로 구성되는 것을 특징으로 하는 의약 생성물.
  4. 부형제와 조합하여 제1항에 따른 화합물을 함유하는 것을 특징으로 하는 약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950020426A 1994-07-13 1995-07-12 알파-(4-클로로페닐)-4-((4-플루오로페닐)메틸)피페리딘-1-에탄올에스테르,그것의제법및치료학적적용 KR960004322A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR94.08711 1994-07-13
FR9408711A FR2722497B1 (fr) 1994-07-13 1994-07-13 Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
KR960004322A true KR960004322A (ko) 1996-02-23

Family

ID=9465359

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950020426A KR960004322A (ko) 1994-07-13 1995-07-12 알파-(4-클로로페닐)-4-((4-플루오로페닐)메틸)피페리딘-1-에탄올에스테르,그것의제법및치료학적적용

Country Status (19)

Country Link
US (1) US5620990A (ko)
EP (1) EP0692472A1 (ko)
JP (1) JPH0859616A (ko)
KR (1) KR960004322A (ko)
CN (1) CN1120038A (ko)
AU (1) AU695312B2 (ko)
CA (1) CA2153726A1 (ko)
CZ (1) CZ180795A3 (ko)
FI (1) FI953410A (ko)
FR (1) FR2722497B1 (ko)
HU (1) HU215599B (ko)
IL (1) IL114562A (ko)
NO (1) NO304427B1 (ko)
NZ (1) NZ272552A (ko)
PL (1) PL309589A1 (ko)
RU (1) RU95113144A (ko)
SK (1) SK88795A3 (ko)
TW (1) TW374084B (ko)
ZA (1) ZA955801B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1151130C (zh) * 1994-08-18 2004-05-26 辉瑞大药厂 神经保护的3-(哌啶基-1)-苯并二氢吡喃-4,7-二醇和1-(4-氢化苯基)-2-(哌啶基-1)链烷醇衍生物
EP1034783B1 (en) * 1997-10-27 2004-12-15 Sumitomo Pharmaceuticals Company, Limited Amide derivatives for the treatment of retinal neurodegenerative disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
FR2628740B3 (fr) * 1989-04-12 1990-01-19 Synthelabo Procede de preparation des enantiomeres du (chloro-4 phenyl)-1 (((fluoro-4 phenyl)methyl)-4 piperidyl-1)-2 ethanol
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
FR2694555A1 (fr) * 1992-08-05 1994-02-11 Synthelabo Procédé de péparation des énantiomères du 1-(4-chloro-2-hydroxyphényl)-2-[4-[(4-fluorophényl)méthyl]-piperidin-1-yl]éthanol.
US5434171A (en) * 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates

Also Published As

Publication number Publication date
HU9502113D0 (en) 1995-09-28
HUT73137A (en) 1996-06-28
HU215599B (hu) 1999-01-28
CZ180795A3 (en) 1996-01-17
TW374084B (en) 1999-11-11
ZA955801B (en) 1996-04-25
FI953410A (fi) 1996-01-14
US5620990A (en) 1997-04-15
IL114562A0 (en) 1995-11-27
NO952761L (no) 1996-01-15
AU695312B2 (en) 1998-08-13
JPH0859616A (ja) 1996-03-05
EP0692472A1 (fr) 1996-01-17
IL114562A (en) 1999-11-30
CN1120038A (zh) 1996-04-10
AU2492295A (en) 1996-01-25
CA2153726A1 (en) 1996-01-14
NO304427B1 (no) 1998-12-14
SK88795A3 (en) 1996-02-07
RU95113144A (ru) 1997-06-27
FR2722497A1 (fr) 1996-01-19
FR2722497B1 (fr) 1996-08-14
FI953410A0 (fi) 1995-07-12
NZ272552A (en) 1996-06-25
NO952761D0 (no) 1995-07-12
PL309589A1 (en) 1996-01-22

Similar Documents

Publication Publication Date Title
AU7503087A (en) Amide derivatives
KR950010893A (ko) 자궁내막증 억제 방법
NO902800D0 (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
KR890005031A (ko) L-도파유도체 또는 그의 산부가염, 그의 제조방법 및 그의 용도
KR950016722A (ko) Ldl 산화 및 죽상동맥경화증의 억제 방법
PT88503A (pt) Procede pour la preparation de derives de (benzyl piperidino)-1propanol-2
ATE266641T1 (de) Picolinsäure-derivate zur behandlung von il-1 und tnf bedingten erkrankungen
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
DE69202166D1 (de) Verwendung von Tetrahydrothienopyridinderivate als Angiogenese-Inhibitoren.
KR960004322A (ko) 알파-(4-클로로페닐)-4-((4-플루오로페닐)메틸)피페리딘-1-에탄올에스테르,그것의제법및치료학적적용
MX9200777A (es) 4-[(2-benzotiazolil)metilamino]-alfa-[(3,4-difluorofenoxi)metil]-1-pip eridetanol.
ATE149165T1 (de) Stickstoff enthaltende bizyklische derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
KR910009257A (ko) 이펜프로딜 및 그의 유도체를 유효성분으로 하는 정신병치료제
SE7909514L (sv) Nya halofenyl-pyridyl-allylaminderivat
KR970010766A (ko) 피페리디닐메틸옥사졸리딘온
KR900018128A (ko) 카르복스아미드 유도체
GB9126874D0 (en) Medicaments
CA2429267A1 (fr) Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
DE59004292D1 (de) Renin-hemmende Aminooligohydroxy-Derivate.
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
BR9504004A (pt) Composto processo para sua preparação e composição farmacêutica
KR970705386A (ko) 치아 및 구강 뼈의 유지방법(methods of maintaining teeth and oralbone)
DE69908855D1 (de) 9a, 11b-dehydro Derivative von 9-oxime-3-keto-6-0-methylerythromycin
KR920019734A (ko) 페닐술포닐알칸산 화합물

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid